Antibiofilm formulations
Methods and compositions related to molecules and formulations comprising antibiofilm materials are provide, including new formulations of Deep Eutectic Solvents (DES) that are chemically related to choline geranate. Specifically, geranic acid (a component of choline geranate DES) is a molecule from the isoprenoid/terpene family of compounds. Other members of this family as DES components include isoprenoid acids and chemical derivatives thereof.
1. An ionic liquid matrix comprising:
a neutral species;
an isoprenoid anion; and
a cholinium cation,
wherein the neutral species, the isoprenoid anion, and the cholinium cation are present in a molar ratio of 1:1:1, and
wherein the neutral species is selected from the group consisting of carvacrol, citronellic acid and farnesol.
2. The ionic liquid matrix of claim 1 , wherein the isoprenoid anion is selected from the group consisting of geranate anion, citronellate anion, cinnamate anion, gibberelate anion, isovalerate anion, absciscate anion, indole-3-butyrate anion, salicylate anion, protocatechuate anion and abietate anion.
3. An antibiofilm material, comprising
the iconic liquid matrix of claim 1 ; and
a solvent.
4. The antibiofilm material of claim 3 , wherein the ionic liquid matrix is present in the antibiofilm material at a concentration of from 0.01% by volume to 20% by volume.
5. The antibiofilm material of claim 3 , wherein the ionic liquid matrix is present in the antibiofilm material at a concentration of from 0.1% by volume to 15% by volume.
6. The antibiofilm material of claim 3 , wherein the ionic liquid matrix is present in the antibiofilm material at a concentration of from 1% by volume to 10% by volume.
7. The antibiofilm material of claim 3 , further comprising a compound exhibiting stabilizing or preservative activity.
8. The antibiofilm material of claim 4 , wherein the compound exhibiting stabilizing or preservative activity is selected from the group consisting of α-tocopherol, α-tocopherol acetate, β-carotene, lutein, salicylic acid, protocatechuic acid.
9. The antibiofilm material of claim 7 , wherein the compound exhibiting stabilizing or preservative activity is present at a concentration of 0.1% by volume to 5% by volume.
10. The antibiofilm material of claim 7 , wherein the compound exhibiting stabilizing or preservative activity is present at a concentration of 1% by volume to 2% by volume.
11. A method of killing a bacterium, comprising:
contacting a bacterium with the antibiofilm material of claim 3 , whereby the bacterium is killed.
12. The method of claim 11 , wherein the bacterium is selected from the group consisting of Staphylococcus aureus, Pseudomonas aeruginosa, Enterobacter cloacae, Enterococcus sp., and Escherichia coli, Acinetobacter baumani , and Klebsiella pneumoniae.
13. A cleaning solution comprising the antibiofilm material of claim 3 .
14. A delivery vehicle for an antibiofilm drug comprising the antibiofilm material of claim 3 .
15. The ionic liquid matrix of claim 1 , wherein the neutral species is carvacrol.
16. The ionic liquid matrix of claim 1 , wherein the neutral species is citronellic acid.
17. The ionic liquid matrix of claim 1 , wherein the neutral species is farnesol.